CN120202212A - 一种多肽抑制剂、其制备方法和应用 - Google Patents

一种多肽抑制剂、其制备方法和应用 Download PDF

Info

Publication number
CN120202212A
CN120202212A CN202380079192.7A CN202380079192A CN120202212A CN 120202212 A CN120202212 A CN 120202212A CN 202380079192 A CN202380079192 A CN 202380079192A CN 120202212 A CN120202212 A CN 120202212A
Authority
CN
China
Prior art keywords
amino acids
alkyl
integer
added
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380079192.7A
Other languages
English (en)
Chinese (zh)
Inventor
董加强
俞文胜
陈运
程宝
龚珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN120202212A publication Critical patent/CN120202212A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202380079192.7A 2022-11-30 2023-11-30 一种多肽抑制剂、其制备方法和应用 Pending CN120202212A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202211530438 2022-11-30
CN2022115304381 2022-11-30
CN2023102062995 2023-03-03
CN202310206299 2023-03-03
CN202310261818 2023-03-15
CN2023102618188 2023-03-15
CN202310349519 2023-03-31
CN202310349519X 2023-03-31
CN2023111444895 2023-09-05
CN202311144489 2023-09-05
PCT/CN2023/135637 WO2024114762A1 (zh) 2022-11-30 2023-11-30 一种多肽抑制剂、其制备方法和应用

Publications (1)

Publication Number Publication Date
CN120202212A true CN120202212A (zh) 2025-06-24

Family

ID=91323029

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380079192.7A Pending CN120202212A (zh) 2022-11-30 2023-11-30 一种多肽抑制剂、其制备方法和应用

Country Status (10)

Country Link
US (1) US20260193294A1 (cg-RX-API-DMAC7.html)
EP (1) EP4628499A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025540765A (cg-RX-API-DMAC7.html)
KR (1) KR20250111134A (cg-RX-API-DMAC7.html)
CN (1) CN120202212A (cg-RX-API-DMAC7.html)
AU (1) AU2023404553A1 (cg-RX-API-DMAC7.html)
IL (1) IL321139A (cg-RX-API-DMAC7.html)
MX (1) MX2025006152A (cg-RX-API-DMAC7.html)
TW (1) TW202440611A (cg-RX-API-DMAC7.html)
WO (1) WO2024114762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242221A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 新型修饰侧链、其制备方法和应用
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026052109A1 (zh) * 2024-09-06 2026-03-12 上海翰森生物医药科技有限公司 一种多肽抑制剂的药物组合物及其用途
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810154WA (en) * 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP4021919A1 (en) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
MX2022008740A (es) * 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) * 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) * 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor

Also Published As

Publication number Publication date
IL321139A (en) 2025-07-01
JP2025540765A (ja) 2025-12-16
MX2025006152A (es) 2025-07-01
US20260193294A1 (en) 2026-07-09
AU2023404553A1 (en) 2025-07-10
TW202440611A (zh) 2024-10-16
WO2024114762A1 (zh) 2024-06-06
KR20250111134A (ko) 2025-07-22
EP4628499A1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
TWI862640B (zh) 異質雙環肽複合物
KR20250111134A (ko) 폴리펩티드 억제제, 이의 제조 방법 및 응용
US20240148916A1 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
US20240352073A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
WO2020259258A1 (zh) 一种抗体偶联药物、其中间体、制备方法及应用
CZ285104B6 (cs) Deriváty kyseliny žlučové, způsob jejich přípravy a použití těchto sloučenin jako léčiv
US20110301087A1 (en) Crf1 receptor compounds
JPH06503090A (ja) ノナペプチドのボンベシン拮抗薬
TW202327620A (zh) 一種抗炎症的化合物及其用途
TW202435884A (zh) 用於抑制tnf受體1活性之環狀肽
CN120390747A (zh) 用于靶向递送应用的碳酸酐酶ix配体
CN112851755B (zh) 一种线性脂肽化合物及其制备方法与应用
SCHULTZ et al. Synthesis and conformational properties of a synthetic cyclic peptide for the active site of α‐chymotrypsin
CA2061993A1 (en) Fucose-bearing cytostatics
TW201536815A (zh) 血管加壓素-2受器促效劑
CN114634551B (zh) 多肽及其在制备拮抗野生型p53与MDM2结合的抗癌药物中的应用
RU2800137C1 (ru) Конъюгат антитело-лекарственное средство, промежуточное соединение для его получения, способ его получения и его применение
EP4471049A1 (en) Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) Peptide inhibitors of interleukin-23 receptor
CN109415378B (zh) 水溶性Epothilone衍生物及其制备方法
WO2023088236A1 (zh) Mt1-mmp的双环肽配体及其缀合物
EP4652182A1 (en) Peptide inhibitors of interleukin-23 receptor
JPS6110553A (ja) プロリン誘導体
CA3191963A1 (en) Thionoester-derivative of rabeximod for the treatment of inflammatory and autoimmune disorders
JPH0482899A (ja) ペプチドまたはその塩およびそれらを含有する甲状腺機能亢進症の診断薬または治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40124253

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination